AILIM/ICOS: Its Expression and Functional Analysis with Monoclonal Antibodies
- 1 October 2001
- journal article
- research article
- Published by Mary Ann Liebert Inc in Hybridoma and Hybridomics
- Vol. 20 (5-6), 293-303
- https://doi.org/10.1089/15368590152740699
Abstract
Activation-inducible lymphocyte immuno-mediatory molecule (AILIM/ICOS) is the third member of the co-stimulatory molecule CD28/CTLA-4 (CD152) family, and an inducible cell surface glycoprotein expressed on lymphocytes following activation. To determine the expression profile of the molecule, we generated monoclonal antibodies (MAbs) against human, rat, and mouse AILIM/ICOS. None of the MAbs bound to AILIM/ICOS of other species. The numbers of AILIM/ICOS-positive cells among human peripheral blood mononuclear cells (PBMC), and rat and mouse splenocytes were very low (0.5, 0.4, and 1.2%, respectively), and the cells included many CD4-positive T cells except in the case of rat. Rat AILIM/ICOS-positive cells among splenocytes included many CD45RA-positive B cells, although the expression on lymph node cells was similar to that on human PBMC and mouse splenocytes. Among rat thymocytes, the AILIM/ICOS expression was mainly localized on CD4- and CD8-double positive T cells. The binding of AILIM/ICOS to B7h-Ig, which is the ligand-Fc chimeric protein, was inhibited by all AILIM/ICOS-specific MAbs except for SG430. The potency of the co-stimulatory activity of CD3 and AILIM/ICOS as to T-cell proliferation was found to be substantial in human. Interestingly, the levels of stimulation with the two types of MAbs were equal to that with CD3 and CD28 despite the different functions of the two MAbs in the AILIM/ICOS-B7h interaction. On the other hand, the potencies in rat and mouse, although two independent MAbs were tested, were relatively lower than that of CD28-mediated co-stimulation.Keywords
This publication has 36 references indexed in Scilit:
- Identification and Characterization of Rat AILIM/ICOS, a Novel T-Cell Costimulatory Molecule, Related to the CD28/CTLA4 FamilyBiochemical and Biophysical Research Communications, 2000
- Characterization of a novel human surface molecule selectively expressed by mature thymocytes, activated T cells and subsets of T cell lymphomasEuropean Journal of Immunology, 1999
- Accessory Molecule and Costimulation Requirements for CD4 T Cell ResponseCritical Reviews in Immunology, 1997
- CTLA-4 engagement inhibits IL-2 accumulation and cell cycle progression upon activation of resting T cells.The Journal of Experimental Medicine, 1996
- Human B7-1 (CD80) and B7-2 (CD86) bind with similar avidities but distinct kinetics to CD28 and CTLA-4 receptorsImmunity, 1994
- The B7 and CD28 receptor familiesImmunology Today, 1994
- The Role of the CD28 Receptor During T Cell Responses to AntigenAnnual Review of Immunology, 1993
- CTLA-4 is a second receptor for the B cell activation antigen B7.The Journal of Experimental Medicine, 1991
- A Cell Culture Model for T Lymphocyte Clonal AnergyScience, 1990
- CD44 is the principal cell surface receptor for hyaluronateCell, 1990